+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Eluting Stents (DES) (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021

  • ID: 5460002
  • Report
  • October 2021
  • Region: Global
  • 140 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Abbott Vascular Inc
  • Biotronik AG
  • Columbia University
  • Elixir Medical Corp
  • Kaneka Corp
  • MicroPort Scientific Corp
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Drug Eluting Stents (DES) (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021

Summary


This Medical Devices sector report, “Drug Eluting Stents (DES) (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery. One unit refers to one drug eluting stent system.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope


  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy


The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Vascular Inc
  • Biotronik AG
  • Columbia University
  • Elixir Medical Corp
  • Kaneka Corp
  • MicroPort Scientific Corp

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Drug Eluting Stents (DES) Overview
3 Products under Development
3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory
3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials
4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
5 Drug Eluting Stents (DES) Companies and Product Overview
5.1 Abbott Vascular Inc Company Overview
5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Adcomp Technologies Inc. Company Overview
5.2.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.3 Advanced Bifurcation Systems Inc Company Overview
5.3.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Aeon Bioscience Company Overview
5.4.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
5.5 AlviMedica Medical Technologies Inc Company Overview
5.5.1 AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.6 B. Braun Melsungen AG Company Overview
5.6.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
5.7 Biosensors International Group Ltd Company Overview
5.7.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 Biotronik AG Company Overview
5.8.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
5.9 Biotronik SE & Co KG Company Overview
5.9.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
5.10 Boston Scientific Corp Company Overview
5.10.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.11 Cardionovum GmbH Company Overview
5.11.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.12 Cardiorev Pte Ltd (Inactive) Company Overview
5.12.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.13 Columbia University Company Overview
5.13.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
5.14 Concept Medical Inc Company Overview
5.14.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.15 Cordis Corp Company Overview
5.15.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
5.16 DISA Vascular (Pty) Ltd Company Overview
5.16.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.17 Elixir Medical Corp Company Overview
5.17.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
5.18 Envision Scientific Pvt Ltd Company Overview
5.18.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.19 I.B.S. S.p.A. Company Overview
5.19.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
5.20 InspireMD Inc Company Overview
5.20.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
5.21 JW Medical Systems Ltd Company Overview
5.21.1 JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.22 Kaneka Corp Company Overview
5.22.1 Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
5.23 Liaoning Biomedical Materials R&D Center Co Ltd Company Overview
5.23.1 Liaoning Biomedical Materials R&D Center Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.24 MangoGen Pharma Inc Company Overview
5.24.1 MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
5.25 Medinol Ltd Company Overview
5.25.1 Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.26 Medlogics Device Corp (Inactive) Company Overview
5.26.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.27 Medtronic Plc Company Overview
5.27.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
5.28 MicroPort Scientific Corp Company Overview
5.28.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
5.29 MIV Therapeutics Inc Company Overview
5.29.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.30 NuVascular Technologies Inc Company Overview
5.30.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.31 Relisys Medical Devices Ltd Company Overview
5.31.1 Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.32 REVA Medical Inc Company Overview
5.32.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.33 Sahajanand Medical Technologies Pvt Ltd Company Overview
5.33.1 Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.34 Shanghai Bio-heart Biological Technology Co Ltd Company Overview
5.34.1 Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.35 Sino Medical Sciences Technology Inc Company Overview
5.35.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
5.36 Stentys SA Company Overview
5.36.1 Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
5.37 Svelte Medical Systems Inc Company Overview
5.37.1 Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
5.38 Terumo Corp Company Overview
5.38.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
5.39 Terumo Interventional Systems Company Overview
5.39.1 Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
5.40 TissueGen Inc Company Overview
5.40.1 TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
5.41 University of Strathclyde Company Overview
5.41.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
5.42 VasoTech Inc. Company Overview
5.42.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
6 Drug Eluting Stents (DES)- Recent Developments
6.1 Sep 15, 2021: Opto Circuits Announces Unaudited Standalone Financial Results For The First Quarter Ended 30th June 2021
6.2 Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting
6.3 Aug 17, 2021: Opto Circuits (India) Announces Financial Results for the Year Ended 31st March 2021
6.4 Aug 17, 2021: Opto Circuits (India) Announces Board Changes
6.5 Aug 04, 2021: Terumo Revises its Full-Year Financial Guidance for FY2021
6.6 Aug 04, 2021: Terumo Corp. Announces Consolidated Financial Results for the First Quarter Ended June 30, 2021
6.7 Jun 30, 2021: B. Braun Announces Jennifer Prioleau as New Chief Legal Officer and Chief Compliance Officer
6.8 May 24, 2021: Boston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference
6.9 Mar 22, 2021: Terumo and Allied Telesis jointly develop a smooth operating environment for infusion systems
6.10 Feb 18, 2021: Paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs): Reconfirmed position on use in patients with intermittent claudication and critical limb ischaemia
6.11 Feb 17, 2021: Medtronic Executives to Speak at Upcoming Investor Conferences
6.12 Feb 16, 2021: Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2021
6.13 Feb 13, 2021: Opto Circuits (India) announces Un Audited Results For The Third Quarter Ended 31St December 2020
6.14 Feb 12, 2021: Boston Scientific Announces February and March 2021 Conference Schedule
6.15 Feb 04, 2021: Terumo announce Financial Statements
6.16 Jan 06, 2021: Abbott Hosts Conference Call for Fourth-Quarter Earnings
6.17 Oct 23, 2020: Mentice receives order of total SEK 7.1 million from ABBOTT
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
  • XIENCE BIOPRIME - Product Status
  • XIENCE BIOPRIME - Product Description
  • Xience Max - Product Status
  • Xience Max - Product Description
  • Xience SBA Everolimus Eluting Coronary Stent System - Product Status
  • Xience SBA Everolimus Eluting Coronary Stent System - Product Description
  • XIENCE Thin man DES - Product Status
  • XIENCE Thin man DES - Product Description
  • ZoMaxx Drug Eluting Coronary Stent System - Product Status
  • ZoMaxx Drug Eluting Coronary Stent System - Product Description
  • Abbott Vascular Inc - Ongoing Clinical Trials Overview
  • Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
  • Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
  • Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Dual Drug Eluting Stent - Product Status
  • Dual Drug Eluting Stent - Product Description
  • Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • ABS Stenting System - Drug Eluting Stent - Product Status
  • ABS Stenting System - Drug Eluting Stent - Product Description
  • Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
  • Drug Eluting Stent - Product Status
  • Drug Eluting Stent - Product Description
  • AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Cre8 DES - Product Status
  • Cre8 DES - Product Description
  • Cre8 EVO DES - Product Status
  • Cre8 EVO DES - Product Description
  • DES - Coracto - Product Status
  • DES - Coracto - Product Description
  • AlviMedica Medical Technologies Inc - Ongoing Clinical Trials Overview
  • Cre8 DES - A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
  • Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
  • Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
  • Cre8 DES - Safety and Performance Assessment of Coronary Drug-eluting Stent CRE8: Post-market Observational Study
  • Cre8 DES - Second-generation Drug-eluting Stents in Diabetes: A Randomized Trial: The SUGAR Trial
  • Cre8 EVO DES - Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent versus the Synergy Everolimus-eluting Stent and a Personalized versus Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention
  • B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
  • Coroflex DEBlue - Product Status
  • Coroflex DEBlue - Product Description
  • Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • BioFreedom Ultra - Product Status
  • BioFreedom Ultra - Product Description
  • Biosensors International Group Ltd - Ongoing Clinical Trials Overview
  • BioFreedom Ultra - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
  • BioFreedom Ultra - A Randomized Controlled Comparison Between One Versus More than Six Months of Dual Antiplatelet Therapy after Biolimus A9-eluting Stent Implantation
  • BioFreedom Ultra - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
  • BioFreedom Ultra - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
  • BioFreedom Ultra - Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy
  • BioFreedom Ultra - Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
  • BioFreedom Ultra - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
  • BioFreedom Ultra - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
  • BioFreedom Ultra - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
  • BioFreedom Ultra - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease
  • Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
  • Coronary Stent System - Product Status
  • Coronary Stent System - Product Description
  • Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status
  • ProGenic Pimecrolimus-eluting Coronary Stent System - Product Description
  • Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • JACTAX Drug Eluting Stent - Product Status
  • JACTAX Drug Eluting Stent - Product Description
  • SYNERGY 48 Stent - Product Status
  • SYNERGY 48 Stent - Product Description
  • SYNERGY XD Stent - Product Status
  • SYNERGY XD Stent - Product Description
  • TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Status
  • TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Description
  • Boston Scientific Corp - Ongoing Clinical Trials Overview
  • SYNERGY XD Stent - Evaluation of Effectiveness and Safety of Synergy XD Stent in Routine Clinical Practice: A Multicenter, Prospective Observational Study
  • SYNERGY 48 Stent - Stent Coverage and Neointimal Tissue Characterization after Extra Long Everolimus - Eluting Stent Implantation: Prospective Study using Optical Coherence Tomography
  • Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • DEBLIMUS - Product Status
  • DEBLIMUS - Product Description
  • PROTECT - Product Status
  • PROTECT - Product Description
  • ReNATURAL (M) - Product Status
  • ReNATURAL (M) - Product Description
  • ReNATURAL (P) - Product Status
  • ReNATURAL (P) - Product Description
  • Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Peptide-Eluting Coronary Stent - Product Status
  • Peptide-Eluting Coronary Stent - Product Description
  • Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • C3 Exoenzyme Coated Stent - Product Status
  • C3 Exoenzyme Coated Stent - Product Description
  • Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Abluminus DES+ - Product Status
  • Abluminus DES+ - Product Description
  • Abluminus NP - Product Status
  • Abluminus NP - Product Description
  • Concept Medical Inc - Ongoing Clinical Trials Overview
  • Abluminus DES+ - A Multicenter, Prospective, Study to Evaluate the Safety and Effcacy of the Abluminus DES+ in an All-Comers Population
  • Abluminus DES+ - A Post Market Registry of Abluminus Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetes Mellitus
  • Abluminus DES+ - A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES for Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: an Investigator-initiated Pilot Study
  • Abluminus DES+ - ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) - First in Men
  • Abluminus DES+ - Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellitus Global - ABILITY Diabetes Global
  • Abluminus DES+ - Randomized Trial Investigating Clinical Outcomes of Two Sirolimus-Eluting Stents in Diabetes Mellitus
  • Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Corio Pimecrolimus-eluting Stent - Product Status
  • Corio Pimecrolimus-eluting Stent - Product Description
  • CYPHER ELITE - Product Status
  • CYPHER ELITE - Product Description
  • NEVO Sirolimus-Eluting Coronary Stent - Product Status
  • NEVO Sirolimus-Eluting Coronary Stent - Product Description
  • Next Generation Coronary Stent - Product Status
  • Next Generation Coronary Stent - Product Description
  • DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Stellium Stent - Product Status
  • Stellium Stent - Product Description
  • Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • Myolimus Eluting Coronary Stent - Durable Polymer - Product Status
  • Myolimus Eluting Coronary Stent - Durable Polymer - Product Description
  • Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Paclitaxel Eluting Stent - Product Status
  • Paclitaxel Eluting Stent - Product Description
  • I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
  • Drug Eluting Stent - Product Status
  • Drug Eluting Stent - Product Description
  • InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
  • MGuard Drug Eluting Stent - Product Status
  • MGuard Drug Eluting Stent - Product Description
  • JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Excel II DES - Product Status
  • Excel II DES - Product Description
  • JW Medical Systems Ltd - Ongoing Clinical Trials Overview
  • Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
  • Excel II DES - A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II with Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery (CREDIT-III)
  • Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
  • MAHOROBA Stent - Product Status
  • MAHOROBA Stent - Product Description
  • Liaoning Biomedical Materials R&D Center Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • YINYI Polymer-free Drug-coated (Paclitaxel) Coronary Stent System - Product Status
  • YINYI Polymer-free Drug-coated (Paclitaxel) Coronary Stent System - Product Description
  • MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Gene-Delivering Stent - Product Status
  • Gene-Delivering Stent - Product Description
  • Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Elunir Elastomer Drug Eluting Stent - Product Status
  • Elunir Elastomer Drug Eluting Stent - Product Description
  • Elunir Elastomer Drug Eluting Stent - 38mm - Product Status
  • Elunir Elastomer Drug Eluting Stent - 38mm - Product Description
  • Elunir Elastomer Drug Eluting Stent - 44mm - Product Status
  • Elunir Elastomer Drug Eluting Stent - 44mm - Product Description
  • Medinol Ltd - Ongoing Clinical Trials Overview
  • Elunir Elastomer Drug Eluting Stent - BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
  • Elunir Elastomer Drug Eluting Stent - BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis - PK Study
  • Elunir Elastomer Drug Eluting Stent - Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial
  • Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • COBRA-Q Drug Eluting Stent - Product Status
  • COBRA-Q Drug Eluting Stent - Product Description
  • Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Drug Filled Stent - Product Status
  • Drug Filled Stent - Product Description
  • Resolute Onyx DES - Bifurcation Lesions - Product Status
  • Resolute Onyx DES - Bifurcation Lesions - Product Description
  • Resolute Onyx DES - DAPT - Product Status
  • Resolute Onyx DES - DAPT - Product Description
  • Medtronic Plc - Ongoing Clinical Trials Overview
  • Resolute Onyx DES - Bifurcation Lesions - A Post-approval Study of the Medtronic Resolute Onyx Zotarolimus-eluting Coronary Stent System
  • MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Fantasy Drug-Eluting Stent - Product Status
  • Fantasy Drug-Eluting Stent - Product Description
  • MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Smart-2 DES - Product Status
  • Smart-2 DES - Product Description
  • Smart-3 DES - Product Status
  • Smart-3 DES - Product Description
  • VESTAsync - Product Status
  • VESTAsync - Product Description
  • NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • NuSpun DE Stent Sheath - Product Status
  • NuSpun DE Stent Sheath - Product Description
  • Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Corel + C Drug Eluting Stent - Product Status
  • Corel + C Drug Eluting Stent - Product Description
  • REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
  • ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
  • ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Status
  • ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Description
  • REVA Medical Inc - Ongoing Clinical Trials Overview
  • ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Pilot Study of the Rezolve Sirolimus-eluting Bioresorbable Coronary Stent
  • ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Safety And Performance Study Of The ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold (RESTORE II Trial)
  • Sahajanand Medical Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Product Status
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Product Description
  • Sahajanand Medical Technologies Pvt Ltd - Ongoing Clinical Trials Overview
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - A Randomized Controlled Trial to Compare the Safety and Efficacy of Sirolimus-eluting Biodegradable Polymer Ultra-thin Stent (SUPRAFLEX Cruz) and Everolimus-eluting Biodegradable Polymer Stent (SYNERGY) in Treatment for Three-vessel Coronary Artery Disease: Multivessel Talent
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Sirolimus-eluting Coronary Stent System in the Treatment of All-comer Patients with Coronary Artery Disease
  • Supraflex Cruz Sirolimus Eluting Cobalt Chromium Coronary Stent System - Post-market Registry to Evaluate the Safety and Efficacy of the the SUPRAFLEX CRUZ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-comer Patient Cohort with Coronary Artery Disease - The Cruz Senior Study
  • Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System - Product Status
  • BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System - Product Description
  • Shanghai Bio-heart Biological Technology Co Ltd - Ongoing Clinical Trials Overview
  • BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System - A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II
  • BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System - A Registry Trial of the Bioheart Rapamycin Drug-eluting Bioresorbable Coronary Stent System in Patients with Coronary Artery Disease: BIOHEART III
  • Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
  • BuMA Supreme DES - Product Status
  • BuMA Supreme DES - Product Description
  • Supreme HT Drug-Eluting Stent - Product Status
  • Supreme HT Drug-Eluting Stent - Product Description
  • Sino Medical Sciences Technology Inc - Ongoing Clinical Trials Overview
  • BuMA Supreme DES - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
  • BuMA Supreme DES - A Prospective, Multicenter First-in-man Trial Program in China to Evaluate the Efficacy and Safety of Buma Supreme (Eg Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Subjects with De Novo Coronary Lesions, RCT Trial
  • BuMA Supreme DES - A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients with de Novo Coronary Lesions, OPC Trial
  • Supreme HT Drug-Eluting Stent - A Prospective, Multi-center, Single-group Target Value Post-marketing Clinical Study to Evaluate the Safety and Effectiveness of the HT Supreme Drug-eluting Stent System in the Treatment of Real-world Patients with Coronary Heart Disease
  • Supreme HT Drug-Eluting Stent - Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated with Unrestricted Use of the Healing-targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy after 1-month of Dual-antiplatelet Therapy
  • Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
  • STENTYS Paclitaxel-Eluting Stent - Product Status
  • STENTYS Paclitaxel-Eluting Stent - Product Description
  • Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Direct Rx - Product Status
  • Direct Rx - Product Description
  • Slender IDS - Product Status
  • Slender IDS - Product Description
  • Svelte Medical Systems Inc - Ongoing Clinical Trials Overview
  • Slender IDS - OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study
  • Slender IDS - The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
  • Direct Rx - OPTIMIZE Sirolimus-eluting Coronary Stent Systems Pharmacokinetics (PK) Study
  • Direct Rx - The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
  • Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
  • ULTIMASTER NAGOMI - Product Status
  • ULTIMASTER NAGOMI - Product Description
  • Ultimaster Tansei - Product Status
  • Ultimaster Tansei - Product Description
  • Terumo Corp - Ongoing Clinical Trials Overview
  • Ultimaster Tansei - A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions
  • Ultimaster Tansei - Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
  • Ultimaster Tansei - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
  • Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold - Product Status
  • Next Generation Ultimaster Drug Eluting Bioresorbable Scaffold - Product Description
  • Next Ultimaster Metallic Drug Eluting Stent - Product Status
  • Next Ultimaster Metallic Drug Eluting Stent - Product Description
  • TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Cardiovascular Stent - Product Status
  • Cardiovascular Stent - Product Description
  • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
  • Drug-Eluting Stent - Product Status
  • Drug-Eluting Stent - Product Description
  • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • PowerStent Coro DES - Product Status
  • PowerStent Coro DES - Product Description
  • Glossary

List of Figures
  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Drug Eluting Stents (DES) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Vascular Inc
  • Adcomp Technologies Inc.
  • Advanced Bifurcation Systems Inc
  • Aeon Bioscience
  • AlviMedica Medical Technologies Inc
  • B. Braun Melsungen AG
  • Biosensors International Group Ltd
  • Biotronik AG
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • Cardionovum GmbH
  • Cardiorev Pte Ltd (Inactive)
  • Columbia University
  • Concept Medical Inc
  • Cordis Corp
  • DISA Vascular (Pty) Ltd
  • Elixir Medical Corp
  • Envision Scientific Pvt Ltd
  • I.B.S. S.p.A.
  • InspireMD Inc
  • JW Medical Systems Ltd
  • Kaneka Corp
  • Liaoning Biomedical Materials R&D Center Co Ltd
  • MangoGen Pharma Inc
  • Medinol Ltd
  • Medlogics Device Corp (Inactive)
  • Medtronic Plc
  • MicroPort Scientific Corp
  • MIV Therapeutics Inc
  • NuVascular Technologies Inc
  • Relisys Medical Devices Ltd
  • REVA Medical Inc
  • Sahajanand Medical Technologies Pvt Ltd
  • Shanghai Bio-heart Biological Technology Co Ltd
  • Sino Medical Sciences Technology Inc
  • Stentys SA
  • Svelte Medical Systems Inc
  • Terumo Corp
  • Terumo Interventional Systems
  • TissueGen Inc
  • University of Strathclyde
  • VasoTech Inc.
Note: Product cover images may vary from those shown